Puma Biotechnology (NASDAQ:PBYI) Announces Quarterly Earnings Results

Puma Biotechnology (NASDAQ:PBYI) released its earnings results on Thursday. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.09 by $0.06, FiscalAI reports. The firm had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $57.50 million. Puma Biotechnology had a return on equity of 20.76% and a net margin of 11.50%.

Here are the key takeaways from Puma Biotechnology’s conference call:

• Q3 revenue was $55.1 million, with net product revenue of $54.1 million, up from $53.6 million in Q2. However, U.S. NERLYNX net sales fell to $50.6 million from $53.6 million, while $3.6 million of product-supply revenue came from international partners.
• NERLYNX demand was mixed: U.S. demand rose 5% year over year but fell 3% quarter over quarter, while new patient starts declined 9% year over year and 13% sequentially. The company also lowered its 2026 product-revenue outlook slightly and cut its royalty forecast to $18–$19 million from $20–$23 million, citing a China royalty-rate reduction after generic market share crossed a threshold.
• Puma raised its full-year 2026 net-income outlook to $20–$22 million from $17–$20 million and expects $10–$12 million in Q4 net income. It ended Q3 with $108.5 million in cash, cash equivalents, and marketable securities and is now debt-free.
• Puma said preliminary ALISCA-Breast1 data supports considering a Phase III alisertib trial; updated interim results are expected at the San Antonio Breast Cancer Symposium in December, with discussions with regulators planned for the first half of 2027. The company also expects additional ALISCA-Lung1 interim data and initial ALISCA-Lung2 data in 2027, though these remain investigational programs.

Puma Biotechnology Price Performance

PBYI stock traded down $1.52 during mid-day trading on Friday, reaching $8.25. The company had a trading volume of 1,279,729 shares, compared to its average volume of 359,117. The stock has a 50 day simple moving average of $9.88 and a two-hundred day simple moving average of $7.99. The company has a market capitalization of $425.87 million, a price-to-earnings ratio of 17.94 and a beta of 1.40. Puma Biotechnology has a 52 week low of $4.57 and a 52 week high of $11.50.

Insider Buying and Selling

In related news, Director Troy Wilson sold 5,000 shares of the firm’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $9.10, for a total value of $45,500.00. Following the completion of the transaction, the director directly owned 54,750 shares of the company’s stock, valued at approximately $498,225. This trade represents a 8.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alessandra Cesano sold 62,150 shares of the business’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $9.12, for a total transaction of $566,808.00. Following the transaction, the director owned 56,700 shares in the company, valued at approximately $517,104. The trade was a 52.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 22.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on PBYI shares. TD Cowen boosted their price objective on shares of Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a research report on Friday, August 7th. Wall Street Zen raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings raised shares of Puma Biotechnology from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $6.00.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company’s lead product is NERLYNX (neratinib), an oral, irreversible tyrosine kinase inhibitor designed to target HER2 and other members of the epidermal growth factor receptor family.

NERLYNX is approved in the United States for the extended adjuvant treatment of adults with early-stage, HER2-positive breast cancer following adjuvant trastuzumab-based therapy.